フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...
MORRISTOWN, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Orexo (STO:ORX) (OTCQX:ORXOY), which develops improved...
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the...
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its...
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its...
TORONTO, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Kerr Mines Inc. (TSX:KER) (OTC:KERMF) (FRA:7AZ1) (“Kerr” or the...
Regulatory News: Orexo AB (publ.) (STO:ORX) announces that the United States District Court for the District of Delaware ruled in Orexo’s...
The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive...
Regulatory News: Orexo (STO:ORX) Strong Zubsolv® and Abstral® revenue growth. Third quarter 2016 · Total net revenues MSEK...
Regulatory News: Orexo (STO:ORX) Orexo AB (publ.) announced today that it has received approval from the US Food and Drug...
· Mundipharma and Orexo make first EU regulatory submission for Zubsolv® (buprenorphine and naloxone) sublingual tablet · Zubsolv was...
The number of shares and votes in Orexo AB (STO:ORX) has changed as a result of the exercise of warrants in connection with the company’s...
Regulatory News: Orexo (STO:ORX) Prior to the Annual General Meeting 2017, Orexo appoints a Nomination Committee which represents...
Orexo AB (publ.) (STO:ORX) announces that the company has resolved to issue and immediately thereafter repurchase 200,000 class C shares. The...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約